Literature DB >> 24194017

The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors.

H H Sung1, J S Ahn, J J Kim, S H Choo, D H Han, S W Lee.   

Abstract

There has been little data regarding the role of intracavernosal injection (ICI) treatment, its discontinuation rate and the reasons of withdrawal in patients with erectile dysfunction (ED) in the era of phosphodiesterase type 5 (PDE5) inhibitors. The aim of this study was to investigate the rate of withdrawal and its associated reasons in patients undergoing ICI therapy. Patients who were prescribed with ICI treatment two times or more were included since the introduction of sildenafil in Korea in 1999. Telephone surveys were performed to evaluate intercourse rates, withdrawal rates and their associated reasons, adverse events and the patients' satisfaction with their sex lives after the ICI treatments. Two hundred and ninety-four men were contacted by telephone. The mean age was 61.8 ± 7.9 years with a follow-up duration of 25.6 ± 32.1 months. At the last follow-up, 79.9% had discontinued the treatment. Most patients had previously failed PDE5 inhibitor treatment prior to the ICI therapy, and more than half had two or more risk factors of ED. Adequate penile rigidity after ICI therapy was restored in 60.2% of patients. The reasons for discontinuation of ICI were poor response (43.1%), inconvenience of use (18.3%), switch to other treatments (10.7%), loss of libido (6.7%), adverse events (5.5%) and return of spontaneous erection (2.8%). Pain was the most common adverse event in the withdrawal group, whereas prolonged erection was most common in the continuing group. Following ICI treatment, PDE5 inhibitors were the most common therapeutic option (63.1%). The overall satisfaction rate regarding sex life was significantly high in the treatment-continuing group. In conclusion, patients on ICI treatment had severe ED and high withdrawal rates in the era of PDE5 inhibitors. The most common reason for treatment discontinuation was poor response. Before initiating ICI treatments, sufficient counselling is necessary.
© 2013 American Society of Andrology and European Academy of Andrology.

Entities:  

Keywords:  PDE5 inhibitor; erectile dysfunction; intracavernosal injection

Mesh:

Substances:

Year:  2013        PMID: 24194017     DOI: 10.1111/j.2047-2927.2013.00155.x

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  9 in total

Review 1.  Psychosocial perspectives on sexual recovery after prostate cancer treatment.

Authors:  Lauren M Walker; Richard J Wassersug; John W Robinson
Journal:  Nat Rev Urol       Date:  2015-03-10       Impact factor: 14.432

Review 2.  Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.

Authors:  Mary Lee; Roohollah Sharifi
Journal:  Drugs Aging       Date:  2018-03       Impact factor: 3.923

3.  Delivery of intracavernosal therapies using needle-free injection devices.

Authors:  D O'Kane; L Gibson; J du Plessis; A Davidson; D Bolton; N Lawrentschuk
Journal:  Int J Impot Res       Date:  2017-07-27       Impact factor: 2.896

Review 4.  Men's beliefs about treatment for erectile dysfunction-what influences treatment use? A systematic review.

Authors:  Paul Williams; Hayley McBain; Aliya Amirova; Stanton Newman; Kathleen Mulligan
Journal:  Int J Impot Res       Date:  2020-03-31       Impact factor: 2.896

Review 5.  What is the current role of intracavernosal injection in management of erectile dysfunction?

Authors:  A I El-Sakka
Journal:  Int J Impot Res       Date:  2016-04-14       Impact factor: 2.896

6.  Erectile dysfunction management after failed phosphodiesterase-5-inhibitor trial: a cost-effectiveness analysis.

Authors:  Rachel A Moses; Ross E Anderson; Jaewhan Kim; Sorena Keihani; James R Craig; Jeremy B Myers; Sara M Lenherr; William O Brant; James M Hotaling
Journal:  Transl Androl Urol       Date:  2019-08

Review 7.  A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil.

Authors:  Jeffery D Evans; Stephen R Hill
Journal:  Patient Prefer Adherence       Date:  2015-08-12       Impact factor: 2.711

8.  Scrotal hemorrhage after testicular sperm aspiration may be associated with phosphodiesterase-5 inhibitor administration: a retrospective study.

Authors:  Yong-Tong Zhu; Rui Hua; Song Quan; Wan-Long Tan; Qing-Jun Chu; Chun-Yan Wang
Journal:  BMC Urol       Date:  2018-02-06       Impact factor: 2.264

9.  An Empirical vs Risk-Based Approach Algorithm to Intracavernosal Injection Therapy: A Prospective Study.

Authors:  Helen Levey Bernie; Robert Segal; Brian Le; Arthur Burnett; Trinity J Bivalacqua
Journal:  Sex Med       Date:  2017-03       Impact factor: 2.491

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.